Original Article

You have full text access to this OnlineOpen article

Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer

  1. Zumre A. Alicikus MD1,
  2. Yoshiya Yamada MD1,
  3. Zhigang Zhang PhD2,
  4. Xin Pei PhD1,
  5. Margie Hunt MA3,
  6. Marisa Kollmeier MD1,
  7. Brett Cox MD1,
  8. Michael J. Zelefsky MD1,†,*

Article first published online: 8 NOV 2010

DOI: 10.1002/cncr.25467

Issue

Cancer

Cancer

Volume 117, Issue 7, pages 1429–1437, 1 April 2011

Additional Information

How to Cite

Alicikus, Z. A., Yamada, Y., Zhang, Z., Pei, X., Hunt, M., Kollmeier, M., Cox, B. and Zelefsky, M. J. (2011), Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer, 117: 1429–1437. doi: 10.1002/cncr.25467

Author Information

  1. 1

    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York

  3. 3

    Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York

  1. †

    Fax: (212) 639-8876

*Department of Radiation Oncology, 1275 York Avenue, New York, NY 10065

Publication History

  1. Issue published online: 18 MAR 2011
  2. Article first published online: 8 NOV 2010
  3. Manuscript Accepted: 4 JAN 2010
  4. Manuscript Revised: 24 DEC 2009
  5. Manuscript Received: 4 SEP 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (391K)

REFERENCES

  • 1
    Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol. 2004; 171: 1132-1136.
  • 2
    Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105.
  • 3
    Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24: 1990-1996.
  • 4
    Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002; 53: 1111-1116.
  • 5
    Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176( 4 pt 1): 1415-1419.
  • 6
    Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008; 71: 330-337.
  • 7
    Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294: 1233-1239.
  • 8
    Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007; 8: 475-487.
  • 9
    Zelefsky MJ, Hunt MA, Fuks Z, et al. Long-term distant metastases-free survival and cause-specific survival outcomes after high dose conformal radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 66( suppl 1): S9-S9.
  • 10
    Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005; 61: 1019-1034.
  • 11
    Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000; 48: 635-642.
  • 12
    Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001; 166: 876-881.
  • 13
    Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000; 55: 241-249.
  • 14
    Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose 3-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999; 85: 2460-2468.
    Direct Link:
  • 15
    Burman CM, Chui CS, Kutcher GJ, et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997: 39: 863-873.
  • 16
    Zelefsky MJ, Happersett L, Leibel SA, et al. The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with 3-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1997; 37: 13-19.
  • 17
    Chui C-S, Spirou SV. Inverse planning algorithms for external beam radiation therapy. Med Dosim. 2001; 26: 189-197.
  • 18
    Mohan R, Wang X, Jackson A, et al. The potential and limitations of the inverse radiotherapy technique. Radiother Oncol. 1994; 32: 232-248.
  • 19
    Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003; 57: 929-943.
  • 20
    Michalski JM, Winter K, Purdy JA, et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003; 56: 192-198.
  • 21
    Kupelian PA, Ciezki J, Reddy CA, Klein EA, Mahadevan A. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 71: 16-22.
  • 22
    Jacob R, Hanlon AL, Horwitz EM, et al. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004; 100: 538-543.
    Direct Link:
  • 23
    Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer. 2007; 110: 68-80.
    Direct Link:
  • 24
    Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008; 71: 1028-1033.
  • 25
    Morgan PB, Hanlon AL, Horwitz EM, et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 1074-1081.
  • 26
    Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 67-74.
  • 27
    Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 980-988.
  • 28
    Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 1124-1129.
  • 29
    Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 3972-3978.
  • 30
    Valicenti RK, Winter K, Cox JD, et al. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys. 2003; 57: 614-620.
  • 31
    Heemsbergen WD, Peeters STH, Koper PCM, Hoogeman MS, Lebesque JV. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys. 2006; 66: 3-10.
  • 32
    Sethi A, Mohideen N, Leybovich L, Mulhall J. Role of IMRT in reducing penile doses in dose escalation for prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 55: 970-978.
  • 33
    Van der Wielen GJ, van Putten WL, Incrocci L. Sexual function after 3-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys. 2007; 68: 479-484.
  • 34
    Chen CT, Valicenti RK, Lu J, et al. Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer? Int J Radiat Oncol Biol Phys. 2001; 50: 591-595.
View Full Article (HTML) Get PDF (391K)